Hi! Dr Weinstein
The focus seems to be dihydropyridine calcium channel antagonists + ACEI/ARB based practice in routine redressal of hypertension and proteinuria reduction, we hardly see any use of novel L/N type Ca channel antagonist Clinidipine despite its existence for a while now, Japanese Nephrology and hypertension community seem to be very positive on its role on hypertension and proteinuria reduction in diabetics and a favorable cardiac remodeling in CKD cohorts consistently.
1) Clin Exp Nephrol. 2013 Feb;17(1):41-50
2) Int J Mol Sci. 2013 Aug 16;14(8)
3) Kidney Int. 2007 Dec;72(12):1543-9 --CARTER STUDY